Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CI
CI logo

CI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
286.189
Open
284.830
VWAP
281.55
Vol
2.45M
Mkt Cap
73.88B
Low
279.200
Amount
688.67M
EV/EBITDA(TTM)
7.16
Total Shares
264.53M
EV
97.16B
EV/OCF(TTM)
11.03
P/S(TTM)
0.27
The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.
Show More

Events Timeline

(ET)
2026-06-11
10:00:00
Employers Consider Reducing GLP-1 Weight Loss Drug Coverage
select
link
2026-05-20 (ET)
2026-05-20
11:50:00
Major Averages Rise as Semiconductor Stocks Rebound
select

News

Newsfilter
7.0
06-11Newsfilter
Employers Plan to Cut GLP-1 Drug Coverage
  • Employer Coverage Changes: According to the Business Group on Health, about 10% of employers plan to drop coverage for GLP-1 weight-loss drugs by 2027, despite 67% of large employers still covering them in 2026, which could lead to increased healthcare costs for employees.
  • Rising Drug Demand: The introduction of oral options has significantly increased demand for GLP-1 drugs, particularly Wegovy and Foundayo, which can reduce weight by 11% and 14% respectively, attracting more patients who have never tried these medications, thereby raising employer costs.
  • Insurance Policy Adjustments: Cigna ceased coverage for weight-loss medications for its employees in July, prompting them to seek discounted prices directly from drug manufacturers' websites, a shift that may influence future drug coverage policies.
  • Market Cost Pressure: Despite a decrease in drug prices, the growing patient population continues to exert significant cost pressure on employers, with industry experts anticipating further reductions in GLP-1 coverage next year.
CNBC
6.5
06-10CNBC
Cigna: A Stable Cash-Generating Stock Amid Market Volatility
  • Steady Earnings Growth: Cigna reported an adjusted EPS of $7.79 in Q1 and raised its full-year guidance to at least $30.35, marking the fifth consecutive quarter of EPS beats, which, while modest, reflects the company's consistent profitability.
  • Supportive Buyback Program: With approximately $2.5 billion remaining on its $6 billion repurchase program, Cigna not only enhances shareholder returns but also supports its stock price, boosting market confidence in its stability.
  • Attractive Valuation: Trading just above $290, Cigna's forward P/E ratio stands at about 9.5x, significantly lower than the S&P's current multiples, while offering a dividend yield of 2.2%, providing investors with a compelling income opportunity.
  • Flexible Options Strategy: By selling the $280 cash-secured put, investors can earn around 2% in about six weeks; if assigned below $280, their effective cost basis drops to approximately $274, enhancing the investment's margin of safety.
stocktwits
9.5
06-09stocktwits
Oscar Health's 2026 Outlook Remains Optimistic
  • Strong Start to 2026: CFO Scott Blackley stated that 2026 is off to a strong start with membership tracking as expected and May healthcare utilization performing better than anticipated, indicating resilience and potential growth opportunities for the company in the market.
  • Financial Performance Exceeds Expectations: Oscar Health reported a first-quarter EPS of $2.07, surpassing the $1.10 estimate, while revenue reached $4.65 billion, although below the $4.92 billion forecast, with adjusted EBITDA hitting $727 million, showcasing enhanced profitability.
  • Market Opportunities Amid Challenges: Despite expectations of a 20% to 30% contraction in the ACA market, Blackley highlighted competitor withdrawals as growth opportunities, particularly in overlapping markets, which could lead to increased market share by 2027.
  • Investor Sentiment Extremely Bullish: According to Stocktwits, retail sentiment for OSCR is extremely bullish, with a 1,283% surge in message volume over 24 hours, reflecting strong market confidence in Oscar's future performance.
CNBC
8.5
06-08CNBC
Novo Nordisk and Eli Lilly Intensify Competition in Obesity Drug Market
  • Prescription Milestone: Novo Nordisk announced that prescriptions for its Wegovy drug have surpassed 3 million in the U.S. market, indicating strong growth in the competitive GLP-1 drug market, even as Eli Lilly launched its own GLP-1 pill, Foundayo.
  • New Medicare Opportunity: Starting in July, millions of Medicare beneficiaries will gain access to GLP-1 drugs for weight loss at $50 per month, significantly reducing the financial burden on patients and potentially boosting Wegovy's market share.
  • New Drug Development Progress: At the conference, Lilly presented Phase 3 data for its experimental drug retatrutide, showing an average weight loss of 28% among patients, which could reshape the obesity treatment landscape, especially among individuals with higher BMIs.
  • Future Product Strategy: Novo Nordisk plans to launch the CagriSema drug, although its efficacy has not surpassed Lilly's Zepbound, the company remains committed to diversifying its cardiometabolic health product line to address market competition and enhance its stock price.
NASDAQ.COM
4.5
06-04NASDAQ.COM
US Stocks Close Mixed: Dow Hits All-Time High
  • Dow Hits Record High: The Dow Jones Industrial Average rose 1.73% to reach an all-time high, reflecting strong rebounds in bank and managed healthcare stocks, despite a 0.53% decline in the Nasdaq 100 due to weakness in technology stocks.
  • Crude Oil Prices Decline: WTI crude oil prices fell over 3%, lowering inflation expectations and pushing the 10-year T-note yield down 2 basis points to 4.47%, providing support for both stock and bond markets, indicating a complex market reaction to economic outlooks.
  • Jobless Claims Rise: Initial jobless claims in the US increased by 13,000 to 225,000, marking a 3.75-month high, suggesting a weaker labor market, although unit labor costs were unexpectedly revised down to 1.8%, easing concerns over wage pressures.
  • Earnings Season Summary: As of Thursday, 83% of the 494 S&P 500 companies reported earnings that beat estimates, with Q1 earnings projected to rise 12% year-over-year, but excluding the tech sector, growth is only about 3%, the lowest in two years, reflecting divergence across industries.
NASDAQ.COM
4.5
06-04NASDAQ.COM
Dow Jones Hits All-Time High Amid Mixed Market Performance
  • Dow Jones High: The Dow Jones Industrial Average surged 1.49% to reach a new all-time high, demonstrating market resilience driven by strong performance in managed healthcare stocks, despite overall market pressures.
  • Tech Sector Decline: Broadcom's stock plummeted over 14% due to disappointing AI revenue forecasts, leading to a broader decline in chipmakers, while CrowdStrike fell more than 8% despite beating Q1 earnings expectations, reflecting market caution towards tech stocks.
  • Mixed Economic Data: Initial jobless claims rose to 225,000, a 3.75-month high, indicating a weaker labor market, while Q1 nonfarm productivity was revised down to 0.3%, below expectations, potentially impacting future economic growth outlooks.
  • Oil Price Impact: WTI crude oil prices fell over 3% amid a ceasefire agreement between Israel and Lebanon, which lowered inflation expectations and provided support for both stock and bond markets, improving investor sentiment.
Wall Street analysts forecast CI stock price to rise
16 Analyst Rating
Wall Street analysts forecast CI stock price to rise
14 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
300.00
Averages
335.63
High
378.00
Current: 0.000
sliders
Low
300.00
Averages
335.63
High
378.00
Barclays
Andrew Mok
Overweight
to
Equal Weight
downgrade
$310 -> $304
AI Analysis
2026-05-26
Reason
Barclays
Andrew Mok
Price Target
$310 -> $304
AI Analysis
2026-05-26
downgrade
Overweight
to
Equal Weight
Reason
Barclays analyst Andrew Mok downgraded Cigna to Equal Weight from Overweight with a price target of $304, down from $310.
Barclays
Overweight
to
Equal Weight
downgrade
$310 -> $304
2026-05-26
Reason
Barclays
Price Target
$310 -> $304
2026-05-26
downgrade
Overweight
to
Equal Weight
Reason
Barclays downgraded Cigna to Equal Weight from Overweight with a price target of $304, down from $310. The company has limited potential upside to earnings estimates given its low exposure to government insurance, the analyst tells investors in a research note. The firm says Cigna also faces uncertainty from its pharmacy benefit manager transition and the pace of moderating investment spend. Barclays sees more risk than reward into the company's September investor day due to commercial attrition and AI-driven job cut risk.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cigna Group (CI.N) is 9.20, compared to its 5-year average forward P/E of 10.67. For a more detailed relative valuation and DCF analysis to assess Cigna Group's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
10.67
Current PE
9.20
Overvalued PE
11.84
Undervalued PE
9.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.77
Current EV/EBITDA
5.14
Overvalued EV/EBITDA
9.85
Undervalued EV/EBITDA
7.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.38
Current PS
0.25
Overvalued PS
0.46
Undervalued PS
0.31

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top high conviction u.s. stocks
Intellectia · 18 candidates
Market Cap: >= 10.00BRegion: USAnalyst Consensus: Strong BuyPe Ttm: <= 25List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Is Index Component: GSPC, NDX, DJI, RUTFree Cash Flow Ttm: >= 0
Ticker
Name
Market Cap$
top bottom
SCHW logo
SCHW
Charles Schwab Corp
158.44B
UBER logo
UBER
Uber Technologies Inc
140.15B
NEM logo
NEM
Newmont Corporation
107.00B
RCL logo
RCL
Royal Caribbean Cruises Ltd
78.95B
CI logo
CI
Cigna Group
78.83B
B logo
B
Barrick Mining Corp
67.35B
what sector is undervalued right now
Intellectia · 90 candidates
Market Cap Category: small, mid, large, megaRelative Vol: >= 1.50Pe Ttm: <= 15Ps Ratio: <= 3.00P/B Ratio: <= 3.00Ev Ebitda: <= 12
Ticker
Name
Market Cap$
top bottom
SHEL logo
SHEL
Shell PLC
248.20B
SONY logo
SONY
Sony Group Corp
116.85B
CI logo
CI
Cigna Group
77.07B
NTES logo
NTES
NetEase Inc
72.42B
VALE logo
VALE
Vale SA
67.67B
ACGL logo
ACGL
Arch Capital Group Ltd
32.72B
top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
give me a selection of long term stocks
Intellectia · 27 candidates
Market Cap: >= 50.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Return On Equity: >= 13.0%Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
META logo
META
Meta Platforms Inc
1.66T
JPM logo
JPM
JPMorgan Chase & Co
775.45B
MU logo
MU
Micron Technology Inc
471.24B
MRK logo
MRK
Merck & Co Inc
287.32B
MS logo
MS
Morgan Stanley
255.47B
GS logo
GS
Goldman Sachs Group Inc
244.45B
name me one concrete stock to buy
Intellectia · 28 candidates
Market Cap: >= 10.00BRegion: USQuarter Revenue Yoy Growth: >= 10.0%Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Is Index Component: GSPCOne Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
DE logo
DE
Deere & Co
163.44B
FE logo
FE
FirstEnergy Corp
28.94B
CTRA logo
CTRA
Coterra Energy Inc
23.80B
MPWR logo
MPWR
Monolithic Power Systems Inc
57.06B
PKG logo
PKG
Packaging Corp of America
22.16B
HUBB logo
HUBB
Hubbell Inc
27.86B
stocks to look into tmr
Intellectia · 9 candidates
Relative Vol: >= 2Is Index Component: GSPCOne Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 5,000,000
Ticker
Name
Market Cap$
top bottom
WAB logo
WAB
Westinghouse Air Brake Technologies Corp
41.66B
ROK logo
ROK
Rockwell Automation Inc
47.41B
EBAY logo
EBAY
eBay Inc
39.08B
IR logo
IR
Ingersoll Rand Inc
38.97B
KKR logo
KKR
KKR & Co Inc
91.54B
EXPE logo
EXPE
Expedia Group Inc
28.41B
which stocks should I buy?
Intellectia · 68 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Beta: LowRisk, ModerateRiskRevenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
Can you add a screener for me?A I
Intellectia · 69 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Revenue 5yr Cagr: >= 5Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
563.46B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
MS logo
MS
Morgan Stanley
290.20B
NVO logo
NVO
Novo Nordisk A/S
263.42B
RY logo
RY
Royal Bank of Canada
235.24B
GILD logo
GILD
Gilead Sciences Inc
160.18B
insiders buying in last 30 days
Intellectia · 505 candidates
Insider Transactions: NetPurchase
Ticker
Name
Market Cap$
top bottom
GE logo
GE
General Electric Co
335.96B
LIN logo
LIN
Linde PLC
205.15B
SPGI logo
SPGI
S&P Global Inc
160.84B
ETN logo
ETN
Eaton Corporation PLC
131.26B
SBUX logo
SBUX
Starbucks Corp
109.65B
NKE logo
NKE
Nike Inc
96.83B
select 5 stocks with strong buy rating
Intellectia · 90 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong BuyPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
BAC logo
BAC
Bank of America Corp
375.55B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
RY logo
RY
Royal Bank of Canada
235.24B
ABT logo
ABT
Abbott Laboratories
209.93B
DIS logo
DIS
Walt Disney Co
202.08B
C logo
C
Citigroup Inc
198.97B

Whales Holding CI

S
Simplex Trading, LLC
Holding
CI
+78.42%
3M Return
W
Wolverine Trading, LLC
Holding
CI
+34.53%
3M Return
W
Walleye Capital LLC
Holding
CI
+31.66%
3M Return
S
Sanders Capital, LLC
Holding
CI
+22.74%
3M Return
I
IMC Trading B.V.
Holding
CI
+21.04%
3M Return
A
Argenta Asset Management SA
Holding
CI
+20.89%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cigna Group (CI) stock price today?

The current price of CI is 279.27 USD — it has decreased -2.04

What is Cigna Group (CI)'s business?

The Cigna Group is a global health company. The Company has two segments: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to customers and clients. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help the clients.

What is the price predicton of CI Stock?

Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is335.63 USD with a low forecast of 300.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cigna Group (CI)'s revenue for the last quarter?

Cigna Group revenue for the last quarter amounts to 68.49B USD, increased 4.57

What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?

Cigna Group. EPS for the last quarter amounts to 6.26 USD, increased 29.07

How many employees does Cigna Group (CI). have?

Cigna Group (CI) has 67700 emplpoyees as of June 21 2026.

What is Cigna Group (CI) market cap?

Today CI has the market capitalization of 73.88B USD.